When it comes to picking shares that will outperform the market, it pays to have a look at what the experts are saying.
I've sifted through the analyst reports released this week and zeroed in on two from Macquarie that have flagged companies they think could notch outsized gains.
Let's have a look at the companies they like.
Image source: Getty Images
Pexa Group Ltd (ASX: PXA)
Shares in this property settlement technology firm have been lacklustre over the past 12 months, returning a negative 16.6% over the period.
This is despite the company recently delivering what it called a "strong" third-quarter performance and reaffirming its FY26 guidance.
Total transaction volumes processed by the Pexa Exchange were 935,000 in the third quarter, up 7.3% from the previous corresponding period, the company said.
Pexa Chief Executive Officer Russell Cohen said regarding the third-quarter results:
We delivered strong performance in the third quarter of FY26 across both Australia and the UK. In Australia, property transaction volumes remained resilient, growing 7% versus the prior year despite market uncertainty and rising interest rates. UK market growth moderated from the first half, with macroeconomic uncertainty impacting volumes in the quarter. Another quarter of robust operational performance and disciplined cost management has positioned us to deliver performance towards the top end of our FY26 NPAT guidance range.
Macquarie said in its research note on Pexa that formal commitments from additional Tier 1 lenders to use the platform would lead to other Tier 1 lenders to "onboard quickly, driving rapid market share gains".
Macquarie has a price target of $19.05 on Pexa shares, compared to $10.53 currently.
Ebos Group Ltd (ASX: EBO)
Ebos Group shares are down slightly more than 50% over the past 12 months; however, the Macquarie team believes the company is well-placed for share price gains.
The company is also paying a dividend yield of 5.9% this year, with that figure expected to increase to 6.9% in 2028.
EBOS in April downgraded its FY26 underlying EBITDA guidance to $610 to $620 million, down from a previous range of $615 to $635 million, due to higher fuel and energy costs.
Macquarie said on the positive side of the ledger, a new First Pharmaceutical Wholesaler Agreement has been struck with the Federal Government, which will benefit EBOS' Symbion division.
Macquarie has a price target of NZ$36.44 on the stock compared with NZ$19.38 at the time of writing.
